The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have awarded Cue Health $481m to produce and deploy six million point-of-care molecular COVID-19 tests by March 2021.
Cue’s COVID-19 test received an emergency use authorization from the US Food and Drug Administration in June
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?